Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TMS-008
- Development stage
- Unknown
- Lead developer
- TMS
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
TMS-008 is a small molecule inhibitor of soluble epoxide hydrolase (sEH) being developed by TMS Co., Ltd. for the treatment of acute kidney injury (AKI) and other inflammatory and fibrotic conditions. The drug works by preventing the metabolic degradation of epoxyeicosatrienoic acids (EETs), which are endogenous lipid mediators that exhibit potent anti-inflammatory, anti-fibrotic, and organ-protective effects. By stabilizing EET levels, TMS-008 aims to mitigate renal damage, reduce inflammation, and promote tissue recovery. It is currently being evaluated in early-stage clinical trials to establish safety and pharmacokinetics in humans.
02
Targets
EPHX2 (Soluble epoxide hydrolase)
Beyond the preview
Go deeper on TMS-008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TMS-008.